Suchergebnisse - "Kuykendall, Andrew T"

PubPharm (63)

1

Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib

enthalten in: JCO precision oncology | 2024

von Kuykendall, A. | Ball, S. | Mora, B. | +12

2

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

enthalten in: American journal of hematology | 2024

von Pandey, G. | Mazzacurati, L. | Rowsell, T. | +10

3

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

enthalten in: The New England journal of medicine | 2024

von Kremyanskaya, M. | Kuykendall, A. | Pemmaraju, N. | +32

4

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

enthalten in: Annals of hematology | 2024

von Horvat, N. | Abdallah, E. | Xie, Z. | +9

5

Interferons in the treatment of myeloproliferative neoplasms

enthalten in: Therapeutic advances in hematology | 2024

von Vachhani, P. | Mascarenhas, J. | Bose, P. | +9

6

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

enthalten in: Annals of hematology | 2023

von Horvat, N. | Abdallah, E. | Xie, Z. | +9

7

A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis

enthalten in: bioRxiv.org | 2023

von Vincelette, N. | Yu, X. | Kuykendall, A. | +23

8

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM) : an updated analysis of an international, double-blind, randomised phase 3 study

enthalten in: The Lancet. Haematology | 2023

von Gerds, A. | Verstovsek, S. | Vannucchi, A. | +25

CommentIn: Lancet Haematol. 2023 Sep;10(9):e697-e699. - PMID 37517412

9

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Patel, M. | Donnellan, W. | Byrne, M. | +10

10

Correction to : Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

enthalten in: Annals of hematology | 2023

von Kuykendall, A.

ErratumFor: Ann Hematol. 2023 May;102(5):985-993. - PMID 36944847

1
2
3
4
5
6
7
Nächster »
[7]